Biodexa Pharmaceuticals Successfully Completes Recruitment of Cohort A in Study of MTX110 for Recurrent Glioblastoma

Biodexa Pharmaceuticals PLC, a clinical stage biopharmaceutical company focused on developing treatments for primary and metastatic brain cancers, has announced the completion of recruitment for cohort A in its Phase 1 study of MTX110 for recurrent glioblastoma (rGBM). The study, known as MAGIC-G1, aims to assess the feasibility and safety of intermittent infusions of MTX110 administered via convection enhanced delivery (CED) in patients with rGBM.

The recruitment of cohort A was concluded after the Data Safety Monitoring Board (DSMB) reviewed the absence of drug-related adverse events and approved the dose escalation to 90µM. Four patients have been recruited for cohort A, with patient 1 receiving 13 treatment cycles over 19 weeks, patient 2 receiving 10 cycles over 13 weeks, patient 3 receiving five cycles to date, and the fourth patient scheduled to receive their first cycle of treatment soon.

Enrollment for cohort B is expected to commence in late October 2023, pending approval from the study DSMB. Additionally, Biodexa plans to add two more investigational centers to the study in December 2023 and January 2024.

Dr Dmitry Zamoryakhin, CSO of Biodexa, expressed delight in completing the recruitment of cohort A with the minimum number of patients due to the absence of drug-related adverse events. He highlighted that cohort B will provide a unique opportunity for continuous CED treatment after in-study tumor progression, which will be the first of its kind.

Glioblastoma (GB) is a devastating primary malignant brain tumor with a high mortality rate. The current standard of care for GB includes surgery, radiotherapy, and chemotherapy. However, almost all patients experience tumor progression, and there is currently no established standard of care for recurrent GB.

MTX110, a water-soluble form of panobinostat, is being evaluated as a potential treatment for recurrent glioblastoma, pediatric DMG, and recurrent medulloblastoma. The drug is delivered directly to the tumor site via convection-enhanced delivery, bypassing the blood-brain barrier and minimizing systemic drug levels.

Biodexa Pharmaceuticals PLC is dedicated to developing innovative therapies for primary and metastatic brain cancers. Its lead candidate, MTX110, holds promise in addressing the urgent medical need for effective treatments in aggressive rare/orphan brain cancer indications.

For more information, please visit www.biodexapharma.com.